Pharmatech

WuXi PharmaTech, PRA form joint venture for Chinese market

Thursday, December 20, 2012 10:32 AM

CRO WuXi PharmaTech, with operations in China and the U.S., and CRO PRA have signed a joint venture agreement to offer a broad platform of phase I-IV clinical trial services in China, Hong Kong and Macau, including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting and medical monitoring.

More... »

Quest PharmaTech receives $8 million investment for oregovomab trials

Wednesday, June 6, 2012 09:32 AM

Quest PharmaTech, an Alberta-based biotech developing and commercializing products for the treatment of cancer, has received an $8 million investment from parties of South Korea to support its clinical trial programs.

More... »

WuXi PharmaTech acquires two clinical research companies in China

Monday, October 24, 2011 11:44 AM

WuXi PharmaTech has acquired MedKey Med-Tech Development and Jiecheng Med-Tech Development, two related contract clinical research services companies based in Shanghai, China. The financial terms of the transaction were not disclosed.

More... »

DIA names director of DIA India

Monday, October 17, 2011 12:00 PM

DIA has named Kaushik Desai as director of DIA India. Kaushik brings to DIA both a deep knowledge of the global regulatory framework and the pharmaceutical environment in India as well as a passion for the vision and mission of the association.

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »

WuXi Reports 36% Revenue Growth, Prepares for Sale to Charles River

Wednesday, May 12, 2010 07:07 AM

Chinese contract research organization WuXi Pharmatech reported 36% revenue growth in what may be one of the company’s last quarterly earnings statements if an acquisition by Charles River Laboratories goes through.

More... »

Charles River Labs to Acquire WuXi PharmaTech for $1.6B

Monday, April 26, 2010 08:32 AM

Preclinical contract research organization (CRO) Charles River Laboratories announced this morning plans to acquire Chinese CRO Wuxi PharmaTech in a deal valued at $1.6 billion.

More... »

WuXi Partners with Janssen to Meet GLP Standards in China Lab

Thursday, March 4, 2010 06:10 AM

Chinese CRO WuXi PharmaTech expanded its strategic collaboration with Johnson & Johnson Pharmaceutical Research and Development(a division of Janssen Pharmaceutica) to provide preclinical services to Janssen and to eventually offer Good Laboratory Practice (GLP) toxicology services at WuXi’s facility in Suzhou, China.

More... »

WuXi Posts Another Strong Quarter

Wednesday, August 12, 2009 06:39 AM

Chinese contract research organization (CRO) WuXi PharmaTech reported another quarter of profit growth with a 7% increase compared to the same period last year despite a drop in revenues.

More... »

Dedicated Phase I Appoints New CMO

Friday, June 26, 2009 10:54 AM

Dedicated Phase I in Phoenix, Ariz., named a new chief medical officer to head its 80-bed phase I clinical research facility. Clark Springgate, M.D., Ph.D., brings more than 25 years' experience to the organization, having directed and participated in more than 256 clinical trials, including first-in-man and first-in-therapeutic-class studies.

More... »